文献速递淋巴瘤

弥漫大B细胞淋巴瘤新型条件无事件生存工具的开发与验证

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.
PubMed 文献 · Am J Hematol · 2026-06-04

研究基于两个观察队列和四项随机试验数据开发条件无事件生存(cEFS)工具,预测弥漫大B细胞淋巴瘤(DLBCL)患者完成一线免疫化疗后缓解期内的复发风险。模型采用年龄、ECOG评分、Ann Arbor分期和LDH四个预测因子,开发队列C-index为0.65,外部验证队列为0.64。该动态工具可辅助医患进行监测和关键决策。

要点

  • cEFS工具可预测DLBCL患者完成一线治疗后基于缓解时间的复发风险。
  • 模型仅需年龄、ECOG评分、Ann Arbor分期和LDH四个基本预测因子。
  • 开发队列C-index为0.65(95%CI 0.63-0.68),外部验证为0.64(95%CI 0.62-0.66)。

核心结论

  • 开发并验证了可动态预测DLBCL患者完成一线治疗后淋巴瘤复发风险的条件无事件生存工具。

研究设计与样本

  • 模型开发使用两个观察性队列和四项随机试验的汇总协调数据,共2757例新诊断DLBCL患者。
  • 纳入患者接受免疫化疗后达到完全缓解或在治疗结束后12周内未发生事件。
  • 采用Cox比例风险回归模型并进行向后逐步选择法建模。
  • 外部验证使用一个大型独立数据注册库。

主要发现

  • 模型开发队列C-index为0.65(95% CI,0.63-0.68),外部验证队列为0.64(95% CI,0.62-0.66)。
  • 仅用年龄、ECOG体能状态分级、Ann Arbor分期和乳酸脱氢酶水平四个基本预测因子即可简洁计算风险。

临床怎么用

  • 该动态风险预测工具有助于临床医生为患者提供数据驱动的监测建议。
  • 可辅助患者进行家庭规划等关键决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One quarter of patients with diffuse large B-cell lymphoma (DLBCL) who achieve a complete response following front-line therapy will eventually experience disease relapse. Existing prognostic models use baseline factors to predict outcomes from the start of initial therapy and are not intended for use following completion of treatment. We developed a conditional event-free survival (cEFS) tool that predicts a patient's risk of lymphoma recurrence after completing front-line therapy taking into consideration baseline risk characteristics plus the time the patient has been in remission. Model development used pooled and harmonized data from two observational cohorts and four randomized trials of patients with newly diagnosed DLBCL treated with immunochemotherapy and either achieving a complete response or not experiencing an event within 12 weeks of end of therapy. Cox proportional-hazards regression modeling with backwards stepwise selection was utilized for model development. External validation was performed using a large independent data registry. In total, data from 2757 patients were used for model development. The risk of experiencing an event at a time point after having survived a period of time could be computed parsimoniously using four basic predictors: age, ECOG performance status grade, Ann Arbor stage, and lactate dehydrogenase level. C-index in the model development cohort was 0.65 (95% CI, 0.63-0.68), compared to 0.64 (95% CI, 0.62-0.66) in the external validation cohort. We believe that this dynamic risk prediction tool will not only aid clinicians in providing data-driven recommendations for surveillance, but also assist patients themselves with key decisions, such as family planning.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chen Z, Luan D, Kragh Jørgensen RR, et al. Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma. Am J Hematol. 2026. PMID: 42240061. doi:10.1002/ajh.70398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。